新型冠状病毒感染特殊人群的抗病毒药物治疗方案  

Antiviral Therapeutics for 2019 Novel Coronavirus Infection in Special Populations

作　　者：李璐[1] 陈娜[1] 孔丽敏[1] 王融溶[1] 王小娟[1] 徐强 阳平[1] 姜赛平[1] 卢晓阳[1] LI Lu;CHEN Na;KONG Limin;WANG Rongrong;WANG Xiaojuan;XU Qiang;YANG Ping;JIANG Saiping;LU Xiaoyang(Department of Pharmacy,The First Affiliated Hospital,College of Medicine,Zhejiang University,Hangzhou 310003,China)

机构地区：[1]浙江大学医学院附属第一医院药学部

出　　处：《中国现代应用药学》2020年第3期257-263,共7页Chinese Journal of Modern Applied Pharmacy

摘　　要：2019年12月新型冠状病毒(2019-nCoV,nCov)在中国武汉爆发,nCov传染性强,目前尚无特效抗病毒治疗方案,基于其他类似病毒的研究,临床试用洛匹那韦/利托那韦、α干扰素、利巴韦林、阿比多尔、达芦那韦考比司他、瑞德西韦等抗nCov感染肺炎。浙江大学医学院附属第一医院作为nCov感染肺炎诊治定点医院承担了浙江省感染患者的收治及抢救重任。基于此,本文针对儿童、孕妇、老年患者、机械通气患者、肝肾功能不全患者、接受体外膜肺氧合或肾脏替代治疗患者等nCov感染特殊人群推荐了可选的抗病毒治疗药物,旨在为患者提供更有效、安全的抗病毒治疗方案。2019 novel coronavirus(2019-nCov, nCov) infections appeared in Wuhan in December 2019, and widespread in China. Currently, there is no specific antiviral drugs for nCov infections. Based on studies of other similar viruses, lopinavir/litonavir, interferon-α, ribavirin, abidol, darunavic/cobicistat and radesivir were used to fight pneumonia caused by nCov infection. The First Affiliated Hospital, College of Medicine, Zhejiang University is the designated hospital for the diagnosis and treatment of nCov infection. Based on this, it is recommend that the optional antiviral drugs for children, pregnant women, elderly patients, patients with mechanical ventilation, liver and kidney dysfunction, patients receving extracorporeal membrane oxygenation or renal replacement therapy with nCov infections, aiming at providing more effective and safe antiviral treatment for patients.

关 键 词：新型冠状病毒 抗病毒药物 特殊人群 

分 类 号：R969.3[医药卫生—药理学]